



April 2026

## ACR Update

Spring has sprung at Austin Clinical Research



### *Why participate in a clinical trial?*

1. Receive specialized care from a team of experienced research staff and board-certified retina surgeons
2. Access to cutting edge treatments that may not be available through standard practices, at no cost to you
3. The opportunity to contribute to the advancement of science
4. A car service is available to bring you to and from appointments during study participation



April 2026

## Enrolling Trials

*(Click on each study name for more info!)*

### Dry Age-Related Macular Degeneration (AMD)

Sanofi DF118231

Character Biosciences CTX114

### Wet Age-Related Macular Degeneration (AMD)

DF117940 Sanofi

Alcon RTE888-E001 Nova-1

Hoffman-La Roche GR40549

4DMT 4D-150-C001 Vector Shedding Substudy

4DMT 4D-150-C004 4FRONT-2

Abbvie ABBV-RGX-314

### Diabetic Macular Edema (DME)

Genentech GR46431

Boehringer-Ingelheim 1485-0018 Thulite (oral agent)

Eyepoint EYP-1901-304 CAPRI

## Study Spotlight

### Abbvie ABBV-RGX-314

A phase 2b/3 study evaluating a one-time gene therapy administration for patients with Wet Age-related Macular Degeneration (AMD). Typical treatment plans for Wet AMD require injections every 4-16 weeks. Gene therapy could potentially eliminate or significantly reduce the treatment burden for people with Wet AMD.

[Click here for more information](#)